US FDA’s Plan On Right To Try: Big On Congressional Engagement, Short On Policy Details

Internal group headed by Principal Deputy Commissioner Rachel Sherman will develop implementation recommendations, which could include new guidance, regulations, a Q&A document or ‘nothing at all,’ Commissioner Gottlieb tells BIO annual meeting; he promises consultation with the law’s supporters and critics on Capitol Hill ‘to fully understand what the intent was with different provisions.’

FDA Commissioner Scott Gottlieb and BIO President and CEO James Greenwood at BIO Annual Meeting
BIO President and CEO James Greenwood has a "fireside chat" with FDA Commissioner Scott Gottlieb at the 2018 annual meeting. • Source: BIO

More from Legislation

More from Pink Sheet